Trial Profile
A Phase III trial of Dexpramipexole for Hypereosinophilic-syndrome
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2022
Price :
$35
*
At a glance
- Drugs Dexpramipexole (Primary)
- Indications Hypereosinophilic syndrome
- Focus Therapeutic Use
- 12 Jul 2022 According to a Knopp Biosciences media release, the company expects to initiate this trial in late 2022.
- 17 May 2018 New trial record
- 10 May 2018 According to a Knopp Biosciences media release, the company expects to initiate this trial later in 2018.